Growth Metrics

ADC Therapeutics (ADCT) Cash from Investing Activities (2019 - 2026)

ADC Therapeutics has reported Cash from Investing Activities over the past 8 years, most recently at -$32000.0 for Q1 2026.

  • Quarterly results put Cash from Investing Activities at -$32000.0 for Q1 2026, up 87.88% from a year ago — trailing twelve months through Mar 2026 was $627000.0 (up 204.5% YoY), and the annual figure for FY2025 was $395000.0, up 145.56%.
  • Cash from Investing Activities reached -$32000.0 in Q1 2026 per ADCT's latest filing, down from $659000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $659000.0 in Q4 2025 and bottomed at -$1.2 million in Q2 2023.
  • Median Cash from Investing Activities over the past 5 years was -$216000.0 (2024), compared with a mean of -$293800.0.
  • The largest annual shift saw Cash from Investing Activities crashed 260136.22% in 2023 before it soared 832.22% in 2025.
  • Over 5 years, Cash from Investing Activities stood at -$684609.0 in 2022, then soared by 52.24% to -$327000.0 in 2023, then soared by 72.48% to -$90000.0 in 2024, then skyrocketed by 832.22% to $659000.0 in 2025, then plummeted by 104.86% to -$32000.0 in 2026.
  • Business Quant data shows Cash from Investing Activities for ADCT at -$32000.0 in Q1 2026, $659000.0 in Q4 2025, and -$264000.0 in Q1 2025.